BBLG$0.369-0.50%
Bone Biologics Corp
Sector: Orthopedic, Prosthetic & Surgical Appliances & SuppliesIndustry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$1.25M
Float & O/S:
Inst Own:
DilutionScan read 32 of Bone Biologics Corp's SEC filings and found 17 warrant series, 1 ATM program, 5 shelf registrations, 2 S-1 registrations and 1 completed offering on file for BBLG. The latest dilution event on file is ATM sales on Sep 30, 2026. Analysis updated Oct 26, 2026.
Signal8 Summary
BBLG
Going-concern warning from auditors
Snapshot
BBLG is a pre-revenue micro-cap developing a bone regeneration device for spinal fusion. The company has generated zero revenue over the last three years and posted a $3.1M net loss in FY 2025.
What's Happening Right Now
- : The validated shelf life of the rhNELL-1 protein was extended to 32 months to support manufacturing and distribution for the upcoming pivotal study.
- : The company secured $3.0 million in gross proceeds from a private placement, which it states extends its operational runway through Q2 2027.
- : Auditors issued a going-concern warning expressing substantial doubt about the company's ability to continue as a going concern within one year.
